Latest Articles

All Latest Articles

149297 Articles

Cheyenne Buckingham | Apr 18, 2018 at 4:18 PM EDT

Most Famous Identical Twins of All Time

[cnxvideo id=”513321″ placement=”ros”]Attempting to achieve stardom is a daunting task, especially when going for it alone. Imagine, though, having someone…

Chris Lange | Apr 18, 2018 at 4:08 PM EDT

Wednesday’s Biggest Winners and Losers in the S&P 500

Wednesday was a mixed day for the broad U.S. markets. It’s possible that all three major indices would have notched…

Paul Ausick | Apr 18, 2018 at 4:04 PM EDT

MGIC, Juniper Networks Slide into Wednesday’s 52-Week Low Club

MGIC Investment Group, Celldex Therapeutics, Juniper Networks, and Healthcare Services Group all posted new 52-week lows on Wednesday.

Paul Ausick | Apr 18, 2018 at 4:01 PM EDT

IBM, Johnson & Johnson Weigh on the Dow Wednesday

The Dow stocks were split between losers and winners Wednesday with IBM and J&J leading the losers while Home Depot…

Paul Ausick | Apr 18, 2018 at 2:00 PM EDT

Starbucks Reputation Gets Decaffeinated

The arrest of two black men in a Philadelphia Starbucks store last week went viral on social media virtually instantly…

Chris Lange | Apr 18, 2018 at 1:25 PM EDT

Will Bed Bath & Beyond Be Put to Sleep?

It seems that things are only getting worse for Bed Bath & Beyond after Standard & Poor’s downgraded its credit…

Jon C. Ogg | Apr 18, 2018 at 1:10 PM EDT

Will Marcus Reshape the Future of Goldman Sachs and Its Image?

Does Goldman Sachs want its Marcus brand to radically change its image, or does it want to keep the "Golden…

Chris Lange | Apr 18, 2018 at 12:25 PM EDT

Why Amex Could Be Poised for a Strong Q1

We shouldn’t expect another big tax charge this quarter, and that’s one reason to be optimistic. However, there are plenty…

Jon C. Ogg | Apr 18, 2018 at 11:45 AM EDT

What Made IBM’s Earnings Beat Look So Bad, and What’s Confusing Analysts and Investors Alike

IBM might have been fine if the company could only get investors to focus on revenues and earnings, but there…

Paul Ausick | Apr 18, 2018 at 11:25 AM EDT

Crude Oil Price Jumps on Inventory Drawdowns

U.S. petroleum inventories fell by modest amounts last week but the declines pushed crude oil prices to a high of…

Chris Lange | Apr 18, 2018 at 11:10 AM EDT

The FDA Strikes Again at Calithera Biosciences

Calithera Biosciences receives a Fast Track designation for its kidney cancer treatment, sending shares higher.

Paul Ausick | Apr 18, 2018 at 10:40 AM EDT

IMF Economic Outlook Mixed on Growth, Future Risks

The April 2018 update to the IMF's World Economic Outlook includes some upbeat forecasts for near-term economic growth but warns…

Chris Lange | Apr 18, 2018 at 10:25 AM EDT

Is This the Turnaround Teligent Has Been Waiting For?

Teligent watched its shares make a solid gain on Wednesday after the firm announced a key approval from the FDA.

Chris Lange | Apr 18, 2018 at 10:20 AM EDT

Rigel Pharmaceuticals Gets No Boost From FDA Approval

Rigel Pharmaceuticals shares retreated early Wednesday despite an approval from the FDA for its treatment of thrombocytopenia.

Lee Jackson | Apr 18, 2018 at 10:05 AM EDT

Why Steel Could Continue to Post Massive Gains All Through 2018

With steel pricing firm, and export potential and demand at home still strong, all four of these stocks make sense…

1 … 4,385 4,386 4,387 4,388 4,389 … 9,954

Latest Articles

All Latest Articles

Most Famous Identical Twins of All Time

Wednesday’s Biggest Winners and Losers in the S&P 500

MGIC, Juniper Networks Slide into Wednesday’s 52-Week Low Club

IBM, Johnson & Johnson Weigh on the Dow Wednesday

Starbucks Reputation Gets Decaffeinated

Will Bed Bath & Beyond Be Put to Sleep?

Will Marcus Reshape the Future of Goldman Sachs and Its Image?

Why Amex Could Be Poised for a Strong Q1

What Made IBM’s Earnings Beat Look So Bad, and What’s Confusing Analysts and Investors Alike

Crude Oil Price Jumps on Inventory Drawdowns

The FDA Strikes Again at Calithera Biosciences

IMF Economic Outlook Mixed on Growth, Future Risks

Is This the Turnaround Teligent Has Been Waiting For?

Rigel Pharmaceuticals Gets No Boost From FDA Approval

Why Steel Could Continue to Post Massive Gains All Through 2018

Why Affluent Couples Are Draining the Higher-Earning Spouse’s 401(k) First to Avoid the Widow’s Tax Penalty

Crypto Crash Today: Why Bitcoin, Ethereum, XRP, and Solana Are All Down Double Digits

Billionaire Bill Ackman’s Pershing Square Exits Universal Music After Failed Takeover Bids, Stock Slumps 7%

Why Affluent Couples Are Draining the Higher-Earning Spouse's 401(k) First to Avoid the Widow's Tax Penalty

Middle-Class Fortysomethings Have a $427,000 Problem and a Shrinking Window to Fix It

Why Affluent Couples Are Draining the Higher-Earning Spouse’s 401(k) First to Avoid the Widow’s Tax Penalty

Crypto Crash Today: Why Bitcoin, Ethereum, XRP, and Solana Are All Down Double Digits

Latest Articles

All Latest Articles

Most Famous Identical Twins of All Time

Wednesday’s Biggest Winners and Losers in the S&P 500

MGIC, Juniper Networks Slide into Wednesday’s 52-Week Low Club

IBM, Johnson & Johnson Weigh on the Dow Wednesday

Starbucks Reputation Gets Decaffeinated

Will Bed Bath & Beyond Be Put to Sleep?

Will Marcus Reshape the Future of Goldman Sachs and Its Image?

Why Amex Could Be Poised for a Strong Q1

What Made IBM’s Earnings Beat Look So Bad, and What’s Confusing Analysts and Investors Alike

Crude Oil Price Jumps on Inventory Drawdowns

The FDA Strikes Again at Calithera Biosciences

IMF Economic Outlook Mixed on Growth, Future Risks

Is This the Turnaround Teligent Has Been Waiting For?

Rigel Pharmaceuticals Gets No Boost From FDA Approval

Why Steel Could Continue to Post Massive Gains All Through 2018

Why Affluent Couples Are Draining the Higher-Earning Spouse’s 401(k) First to Avoid the Widow’s Tax Penalty

Crypto Crash Today: Why Bitcoin, Ethereum, XRP, and Solana Are All Down Double Digits

Billionaire Bill Ackman’s Pershing Square Exits Universal Music After Failed Takeover Bids, Stock Slumps 7%

Featured Reads

Why Affluent Couples Are Draining the Higher-Earning Spouse's 401(k) First to Avoid the Widow's Tax Penalty

Middle-Class Fortysomethings Have a $427,000 Problem and a Shrinking Window to Fix It